Vestas Reports Solid Q3 Revenue but Cuts Full-Year Guidance
Copenhagen-based wind turbine giant Vestas reported Q3 2025 revenue of €5.3 billion (approximately DKK 39.8 billion), a 3% year-over-year increase driven primarily by higher turbine deliveries. Net profit for the quarter reached €304 million (DKK 2.28 billion), reflecting improved execution in key markets.
Onshore turbine deliveries surged in the United States, Sweden, and Ukraine, while offshore activity was bolstered by projects in Poland and Germany. Despite this operational momentum, Vestas has revised its full-year revenue guidance downward, now expecting total 2025 revenue between €18.5 billion and €19.5 billion—below prior expectations.
The adjustment underscores persistent macroeconomic uncertainty, supply chain volatility, and shifting policy landscapes in major markets. Industry analysts note that while delivery volumes are rising, pricing pressure and inflationary costs continue to compress margins, complicating Vestas’ path to sustained profitability.
Ørsted Posts Q3 Loss Amid U.S. Offshore Wind Setbacks
Danish renewable energy leader Ørsted reported a Q3 net loss of DKK 1.7 billion, primarily due to significant impairments linked to its U.S. offshore wind portfolio. The company cited deteriorating project economics and regulatory turbulence—exacerbated by renewed political opposition, including vocal criticism from former U.S. President Donald Trump—as key factors behind the write-downs.
In response, Ørsted suspended construction on one U.S. offshore project and launched a strategic capital raise of DKK 60 billion—the largest in Danish corporate history. This emergency financing, combined with the partial divestment of its stake in the Hornsea 3 offshore wind farm in the UK, has allowed Ørsted to maintain its full-year EBITDA guidance.
However, investor confidence remains fragile. The episode highlights the growing geopolitical and regulatory risks facing European energy firms expanding into the U.S. market, even as global decarbonization goals intensify.
Novo Nordisk Downgrades Outlook for Third Time in Six Months
In a surprising turn for Denmark’s most valuable company, Novo Nordisk has again revised its 2025 financial outlook downward—marking the third guidance cut since May 2025. The pharmaceutical giant now expects full-year sales growth of 8–11%, narrowed from the previous 8–14% range, citing softer-than-expected U.S. demand for its GLP-1 therapies, including Wegovy and Ozempic.
While Q3 sales reached DKK 75 billion and year-to-date performance remains robust, Novo Nordisk faces intensifying competition in the U.S. market, where biosimilar entrants and aggressive pricing by rivals are eroding market share. Regulatory delays and payer pushback on reimbursement have further dampened growth prospects.
Operating profit growth is now forecast at just 4–7% for 2025, down from the earlier 4–10% guidance. CEO Mike Doustdar acknowledged the challenges, stating: “Although we have delivered solid sales progress in the first nine months of 2025, the lower growth expectations for our GLP-1 therapies have led to a narrowing of our forecasts.”
The company is also contending with the financial and operational fallout from a major restructuring announced in September 2025. Novo Nordisk plans to cut 9,000 jobs globally—5,000 of them in Denmark—to free up DKK 8 billion in annual savings by 2027. The layoffs, now underway in Denmark, mark a stark reversal from the rapid hiring spree of 2023–2024, during which the company added over 11,000 employees in Denmark alone, bringing its global headcount to 78,400 before the cuts.
Novo Nordisk’s share price has fallen sharply, trading around DKK 300—down from a peak above DKK 1,000 in early 2024—reflecting investor concerns over sustainability of its hypergrowth narrative.
Analysis: A Trio of Nordic Titans at a Crossroads
The simultaneous recalibrations by Vestas, Ørsted, and Novo Nordisk signal a broader inflection point for Nordic industry leaders. Once buoyed by post-pandemic demand, favourable policy tailwinds, and global leadership in green tech and life sciences, these firms now face converging challenges: regulatory volatility, U.S. market headwinds, intensified global competition, and the limits of rapid scaling.
For investors and policymakers alike, the next 12 months will test whether these companies can successfully pivot from expansion-at-all-costs to disciplined, sustainable growth. The Nordic region’s economic resilience may well hinge on their ability to navigate this transition.
By the Nordic Business Journal Editorial Team
November 5, 2025